Treatment outcomes of multidrug-resistant tuberculosis patients in China: a meta-analysis_Chinese Journal of Evidence-Based Medicine

Authors：

FANG Shilin ¹ ,  WANG Yun ^1,2 , LU Xiaolong ¹ , ZHANG Qiuyu ¹

1. School of Medicine and Health Management, Guizhou Medical University, Guiyang 550025, P.R.China;
2. Key Laboratory of Environmental Pollution Monitoring and Disease Control, Ministry of Education, Guizhou Medical University, Guiyang 550025, P.R.China;

Corresponding?author：

WANG Yun, Email: 441334899@qq.com

Keywords：

Multidrug-resistant tuberculosis; Treatment outcome; Meta-analysis

DOI：

10.7507/1672-2531.202106209

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the treatment outcomes of multidrug-resistant tuberculosis (MDR-TB) patients, and to provide evidence for treatment. Methods Databases including PubMed, Web of Science, ScienceDirect, CNKI, WanFang Data and VIP were electronically searched to collect literature related to MDR-TB from inception to April 28^th, 2021. Two reviewers independently screened literature, extracted data, and assessed the risk of bias of the included studies. Meta-analysis was then performed using R 4.0.5 software, subgroup and meta-regression analyses were performed based on sample size, survey time, etc. Results A total of 36 studies involving 7 981 patients were included. The results of meta-analysis showed that the overall treatment success rate of MDR-TB patients was 60% (95%CI 56% to 63%). The subgroup analysis showed that the treatment success rates of MDR-TB were 49% (95%CI 41% to 58%) from 1992 to 2010, 62% (95%CI 58% to 65%) from 2011 to 2015, and 62% (95%CI 55% to 68%) from 2016 to 2020; those with sample size above 100 and less than 100 were 60% (95%CI 55% to 65%) and 59% (95%CI 54% to 63%), respectively; those with average age above 45 and less than 45 were 58% (95%CI 51% to 65%) and 56% (95%CI 53% to 59%); those of MDR-TB were 63% (95%CI 57% to 68%) in central China, 63% (95%CI 52% to 73%) in the Northwest, 60% (95%CI 55% to 65%) in the Southeast, and 53% (95%CI 48% to 58%) in the Northeast. Conclusions The overall success rate of treatment for MDR-TB patients in China is low. Due to the limited quantity and quality of included studies, more high-quality studies are required to verify the above conclusions.

Citation： FANG Shilin, WANG Yun, LU Xiaolong, ZHANG Qiuyu. Treatment outcomes of multidrug-resistant tuberculosis patients in China: a meta-analysis. Chinese Journal of Evidence-Based Medicine, 2021, 21(11): 1316-1324. doi: 10.7507/1672-2531.202106209 Copy

1.	范琳, 劉一典, 肖和平. 國內《耐藥結核病化學治療指南(2019年)》與相關共識的特色及要點分析. 中國防癆雜志, 2020, 42(2): 91-94.
2.	李志鵬, 盛宇超, 竺麗梅, 等. 徐州市和贛州市耐多藥結核病患者納入治療的影響因素分析. 中國預防醫學雜志, 2020, 21(8): 913-917.
3.	馬慧芬, 孔鵬, 孟慶躍. 耐多藥肺結核治療管理模式現狀. 醫學與哲學, 2012, 33(12): 74-76.
4.	World Health Organization. Global tuberculosis report (2020-10-15). Available at: https://www.who.int/publications/i/item/9789240013131.
5.	周穎, 黃奕祥. 中國耐多藥肺結核患者治療結局的Meta分析. 熱帶醫學雜志, 2016, 16(3): 325-328.
6.	羅杰, 冷衛東. 《系統評價/Meta分析理論與實踐》. 中國循證心血管醫學雜志, 2013, 5(2): 115.
7.	劉志輝, 劉玉美, 伍慧儀, 等. 廣州地區251例耐多藥結核病例分析. 實用醫學雜志, 2005, 21(15): 1712-1714.
8.	郝曉暉, 姚嵐, 唐神結, 等. 初治耐多藥肺結核臨床療效及其轉歸隊列分析. 中華傳染病雜志, 2012, 30(3): 157-161.
9.	杜雨華, 蘇汝釗, 周惠賢, 等. 116例耐多藥肺結核治療轉歸情況影響因素分析. 中國防癆雜志, 2012, 34(1): 19-22.
10.	劉金玲, 羅凱, 崔蘭英. 標準化療方案治療耐多藥肺結核的療效分析. 當代醫學, 2013, (16): 77.
11.	覃紅娟, 譚守勇, 鄺浩斌, 等. 耐多藥肺結核患者住院與門診治療對療效的影響. 實用醫學雜志, 2013, 29(23): 3811-3814.
12.	Tang S, Tan S, Yao L, et al. Risk factors for poor treatment outcomes in patients with MDR-TB and XDR-TB in China: retrospective multi-center investigation. PLoS One, 2013, 8(12): e82943.
13.	孔雯, 劉巧, 陸偉, 等. 標準化耐多藥肺結核化療方案的不良反應及治療轉歸情況分析. 中華疾病控制雜志, 2014, 18(7): 610-612.
14.	丁曉艷, 許衛國, 竺麗梅, 等. 175例耐多藥肺結核患者治療轉歸情況分析. 中國防癆雜志, 2014, 36(4): 238-243.
15.	費宗伍. 230例耐多藥結核病患者的發現和治療情況的研究. 臨床醫藥文獻電子雜志, 2014, (4): 522-523.
16.	郭蘇珊. 75例耐多藥肺結核治療副作用及轉歸分析. 現代醫院, 2015, (3): 68-69,72.
17.	屈亞虹, 朱寧, 馬振亞, 等. 開封市耐多藥肺結核治療管理效果及影響因素分析. 中國防癆雜志, 2015, 37(1): 97-99.
18.	張海清, 孫建勝, 吳云亮, 等. 128例耐多藥肺結核患者的轉歸分析. 徐州醫學院學報, 2015, (8): 534-536.
19.	田曉梅, 石峰, 王曉林, 等. 寧夏耐多藥/廣泛耐藥肺結核患者的發現及治療效果評價. 寧夏醫學雜志, 2015, 37(4): 364-366.
20.	馬俊鋒, 王小平, 陸峰, 等. 南通市全球基金耐多藥結核病項目患者治療情況分析. 南京醫科大學學報(自然科學版), 2015, 35(5): 757-760.
21.	李莉, 孫建勝, 吳云亮. 徐州市完成全球基金耐多藥結核病項目全程治療的耐多藥結核病患者治療效果的影響因素分析. 實用心腦肺血管病雜志, 2015, (7): 50-54.
22.	張志進. 如皋市耐多藥肺結核患者發現, 治療轉歸情況分析. 江蘇預防醫學, 2016, 27(4): 498-499.
23.	劉凡平, 張晨鈺, 王云, 等. 全球基金標準化療方案治療耐多藥肺結核臨床療效評價. 河北醫藥, 2016, 38(7): 1060-1062.
24.	周美蘭, 杜義祥, 王堅杰, 等. 武漢市耐多藥肺結核患者防治模式效果分析. 中國防癆雜志, 2016, 38(11): 918-924.
25.	代曉琦, 阮云洲, 李仁忠, 等. “醫防合作”模式下實施DOT對耐多藥肺結核患者不同治療轉歸的分析. 中國防癆雜志, 2016, 38(11): 929-933.
26.	易恒仲, 羅丹霖, 唐志岡, 等. 湖南省全球基金耐多藥結核病項目患者治療情況分析. 中國熱帶醫學, 2017, 17(3): 244-247.
27.	Lu P, Liu Q, Martinez L, et al. Time to sputum culture conversion and treatment outcome of patients with multidrug-resistant tuberculosis: a prospective cohort study from urban China. Eur Respir J, 2017, 49(3): 1601558.
28.	Alene KA, Yi H, Viney K, et al. Treatment outcomes of patients with multidrug-resistant and extensively drug resistant tuberculosis in Hunan province, China. BMC Infect Dis, 2017, 17(1): 573.
29.	林彬, 楊芳玲, 王先化, 等. 克拉瑪依市與昌吉州耐多藥肺結核轉歸分析. 預防醫學論壇, 2017, 23(2): 107-108,111.
30.	Xu C, Pang Y, Li R, et al. Clinical outcome of multidrug-resistant tuberculosis patients receiving standardized second-line treatment regimen in China. J Infect, 2018, 76(4): 348-353.
31.	Lv L, Li T, Xu K, et al. Sputum bacteriology conversion and treatment outcome of patients with multidrug-resistant tuberculosis. Infect Drug Resist, 2018, 11: 147-154.
32.	Zhang L, Meng Q, Chen S, et al. Treatment outcomes of multidrug-resistant tuberculosis patients in Zhejiang, China, 2009-2013. Clin Microbiol Infect, 2018, 24(4): 381-388.
33.	Fan YM, Ding SP, Bao ZJ, et al. Prognostic factors for treatment success in patients with multidrug-resistant tuberculosis in China. Int J Tuberc Lung Dis, 2018, 22(3): 300-305.
34.	包昌琳, 易恒仲, 唐益, 等. 耐多藥肺結核患者化學治療療效及其影響因素分析. 中國防癆雜志, 2018, 40(5): 525-530.
35.	陳壯濠, 林健雄, 李鴻檳, 等. 汕頭市耐多藥結核病患者治療情況分析. 臨床肺科雜志, 2018, 23(10): 1850-1853.
36.	Chen Y, Yuan Z, Shen X, et al. Time to multidrug-resistant tuberculosis treatment initiation in association with treatment outcomes in Shanghai, China. Antimicrob Agents Chemother, 2018, 62(4): e02259-17.
37.	Li Q, Shi CX, Lu M, et al. Treatment outcomes of multidrug-resistant tuberculosis in Hangzhou, China, 2011 to 2015. Medicine (Baltimore), 2020, 99(30): e21296.
38.	Zheng XB, Diwan VK, Zhao Q, et al. Treatment quality and outcome for multidrug-resistant tuberculosis patients in four regions of China: a cohort study. Infect Dis Poverty, 2020, 9(1): 97.
39.	蔡春葵, 楊連軍, 王申蓮, 等. 316例耐多藥肺結核患者的治療結果分析. 中國醫藥指南, 2020, 18(22): 41-42.
40.	簡麗萍, 郭子玉, 鄧笑媚, 等. 耐多藥肺結核療效影響因素的研究. 中國醫藥科學, 2020, 10(13): 191-194.
41.	Liu Q, Yang D, Qiu B, et al. Drug resistance gene mutations and treatment outcomes in MDR-TB: a prospective study in Eastern China. PLoS Negl Trop Dis, 2021, 15(1): e0009068.
42.	Zhang MW, Zhou L, Zhang Y, et al. Treatment outcomes of patients with multidrug and extensively drug-resistant tuberculosis in Zhejiang, China. Eur J Med Res, 2021, 26(1): 31.
43.	張夢嫻, 楊成鳳, 葉建君, 等. 1447例耐多藥肺結核患者治療轉歸隊列分析. 公共衛生與預防醫學, 2020, 31(3): 68-72.
44.	Arnold A, Cooke GS, Kon OM, et al. Drug resistant TB: UK multicentre study (DRUMS): treatment, management and outcomes in London and West Midlands 2008-2014. J Infect, 2017, 74(3): 260-271.
45.	Riccardi N, Saderi L, Borroni E, et al. Therapeutic strategies and outcomes of MDR and pre-XDR-TB in Italy: a nationwide study. Int J Tuberc Lung Dis, 2021, 25(5): 395-399.
46.	Henry B, Revest M, Dournon N, et al. Preliminary favorable outcome for medically and surgically managed extensively drug-resistant tuberculosis, France, 2009-2014. Emerg Infect Dis, 2016, 22(3): 518-521.
47.	Eshetie S, Alebel A, Wagnew F, et al. Current treatment of multidrug resistant tuberculosis in Ethiopia: an aggregated and individual patients' data analysis for outcome and effectiveness of the current regimens. BMC Infect Dis, 2018, 18(1): 486.
48.	Alemu A, Bitew ZW, Worku T. Poor treatment outcome and its predictors among drug-resistant tuberculosis patients in Ethiopia: a systematic review and meta-analysis. Int J Infect Dis, 2020, 98: 420-439.
49.	Alene KA, Viney K, McBryde ES, et al. Treatment outcomes in patients with multidrug-resistant tuberculosis in north-west Ethiopia. Trop Med Int Health, 2017, 22(3): 351-362.
50.	Ahmed A, Mekonnen D, Shiferaw AM, et al. Incidence and determinants of tuberculosis infection among adult patients with HIV attending HIV care in north-east Ethiopia: a retrospective cohort study. BMJ Open, 2018, 8(2): e016961.
51.	中華人民共和國國務院辦公廳. 全國結核病防治規劃(2011-2015). Available at: http://www.gov.cn/zwgk/2011-12/06/content_2012869.htm.
52.	中華人民共和國國務院辦公廳. 《“十三五”全國結核病防治規劃》. Available at: http://www.gov.cn/xinwen/2017-02/16/content_5168549.htm.
53.	鄺浩斌, 謝育紅, 馮治宇, 等. 2014-2019年廣州市耐多藥肺結核管理策略實施效果分析. 中國防癆雜志, 2021, 43(2): 113-118.
54.	趙秀娟, 劉琳, 吳興勇, 等. 海南省369例耐多藥肺結核患者流行病學特征分析. 海南醫學院學報, 2021. DOI: 10.13210/j.cnki.jhmu.20210413.002.
55.	王云霞, 鄭娟娟, 張娟娟, 等. 2011-2018年寶安區肺結核患者耐多藥的影響因素分析. 預防醫學, 2021, 33(7): 701-703.
56.	全國第五次結核病流行病學抽樣調查技術指導組, 全國第五次結核病流行病學抽樣調查辦公室. 2010年全國第五次結核病流行病學抽樣調查報告. 中國防癆雜志, 2012, 34(8): 485-508.
57.	陜俊玲, 薛王謙, 韓亞男. 涂陽肺結核139例患者分枝桿菌培養及藥敏分析. 中國藥物與臨床, 2013, 13(z1): 10-11.
58.	李秀杰. 172例耐多藥結核病患者特征及治療轉歸的影響因素分析. 中國現代醫生, 2019, 57(7): 30-32.
59.	李雪, 李楠楠, 任斐, 等. 耐多藥肺結核合并糖尿病的臨床特點及治療結局. 中國熱帶醫學, 2021.
60.	周銀發, 張山鷹, 柳珍妮, 等. 242例耐多藥結核病患者特征及治療轉歸的影響因素分析. 中國防癆雜志, 2017, 39(11): 1218-1222.

1. 范琳, 劉一典, 肖和平. 國內《耐藥結核病化學治療指南(2019年)》與相關共識的特色及要點分析. 中國防癆雜志, 2020, 42(2): 91-94.
2. 李志鵬, 盛宇超, 竺麗梅, 等. 徐州市和贛州市耐多藥結核病患者納入治療的影響因素分析. 中國預防醫學雜志, 2020, 21(8): 913-917.
3. 馬慧芬, 孔鵬, 孟慶躍. 耐多藥肺結核治療管理模式現狀. 醫學與哲學, 2012, 33(12): 74-76.
4. World Health Organization. Global tuberculosis report (2020-10-15). Available at: https://www.who.int/publications/i/item/9789240013131.
5. 周穎, 黃奕祥. 中國耐多藥肺結核患者治療結局的Meta分析. 熱帶醫學雜志, 2016, 16(3): 325-328.
6. 羅杰, 冷衛東. 《系統評價/Meta分析理論與實踐》. 中國循證心血管醫學雜志, 2013, 5(2): 115.
7. 劉志輝, 劉玉美, 伍慧儀, 等. 廣州地區251例耐多藥結核病例分析. 實用醫學雜志, 2005, 21(15): 1712-1714.
8. 郝曉暉, 姚嵐, 唐神結, 等. 初治耐多藥肺結核臨床療效及其轉歸隊列分析. 中華傳染病雜志, 2012, 30(3): 157-161.
9. 杜雨華, 蘇汝釗, 周惠賢, 等. 116例耐多藥肺結核治療轉歸情況影響因素分析. 中國防癆雜志, 2012, 34(1): 19-22.
10. 劉金玲, 羅凱, 崔蘭英. 標準化療方案治療耐多藥肺結核的療效分析. 當代醫學, 2013, (16): 77.
11. 覃紅娟, 譚守勇, 鄺浩斌, 等. 耐多藥肺結核患者住院與門診治療對療效的影響. 實用醫學雜志, 2013, 29(23): 3811-3814.
12. Tang S, Tan S, Yao L, et al. Risk factors for poor treatment outcomes in patients with MDR-TB and XDR-TB in China: retrospective multi-center investigation. PLoS One, 2013, 8(12): e82943.
13. 孔雯, 劉巧, 陸偉, 等. 標準化耐多藥肺結核化療方案的不良反應及治療轉歸情況分析. 中華疾病控制雜志, 2014, 18(7): 610-612.
14. 丁曉艷, 許衛國, 竺麗梅, 等. 175例耐多藥肺結核患者治療轉歸情況分析. 中國防癆雜志, 2014, 36(4): 238-243.
15. 費宗伍. 230例耐多藥結核病患者的發現和治療情況的研究. 臨床醫藥文獻電子雜志, 2014, (4): 522-523.
16. 郭蘇珊. 75例耐多藥肺結核治療副作用及轉歸分析. 現代醫院, 2015, (3): 68-69,72.
17. 屈亞虹, 朱寧, 馬振亞, 等. 開封市耐多藥肺結核治療管理效果及影響因素分析. 中國防癆雜志, 2015, 37(1): 97-99.
18. 張海清, 孫建勝, 吳云亮, 等. 128例耐多藥肺結核患者的轉歸分析. 徐州醫學院學報, 2015, (8): 534-536.
19. 田曉梅, 石峰, 王曉林, 等. 寧夏耐多藥/廣泛耐藥肺結核患者的發現及治療效果評價. 寧夏醫學雜志, 2015, 37(4): 364-366.
20. 馬俊鋒, 王小平, 陸峰, 等. 南通市全球基金耐多藥結核病項目患者治療情況分析. 南京醫科大學學報(自然科學版), 2015, 35(5): 757-760.
21. 李莉, 孫建勝, 吳云亮. 徐州市完成全球基金耐多藥結核病項目全程治療的耐多藥結核病患者治療效果的影響因素分析. 實用心腦肺血管病雜志, 2015, (7): 50-54.
22. 張志進. 如皋市耐多藥肺結核患者發現, 治療轉歸情況分析. 江蘇預防醫學, 2016, 27(4): 498-499.
23. 劉凡平, 張晨鈺, 王云, 等. 全球基金標準化療方案治療耐多藥肺結核臨床療效評價. 河北醫藥, 2016, 38(7): 1060-1062.
24. 周美蘭, 杜義祥, 王堅杰, 等. 武漢市耐多藥肺結核患者防治模式效果分析. 中國防癆雜志, 2016, 38(11): 918-924.
25. 代曉琦, 阮云洲, 李仁忠, 等. “醫防合作”模式下實施DOT對耐多藥肺結核患者不同治療轉歸的分析. 中國防癆雜志, 2016, 38(11): 929-933.
26. 易恒仲, 羅丹霖, 唐志岡, 等. 湖南省全球基金耐多藥結核病項目患者治療情況分析. 中國熱帶醫學, 2017, 17(3): 244-247.
27. Lu P, Liu Q, Martinez L, et al. Time to sputum culture conversion and treatment outcome of patients with multidrug-resistant tuberculosis: a prospective cohort study from urban China. Eur Respir J, 2017, 49(3): 1601558.
28. Alene KA, Yi H, Viney K, et al. Treatment outcomes of patients with multidrug-resistant and extensively drug resistant tuberculosis in Hunan province, China. BMC Infect Dis, 2017, 17(1): 573.
29. 林彬, 楊芳玲, 王先化, 等. 克拉瑪依市與昌吉州耐多藥肺結核轉歸分析. 預防醫學論壇, 2017, 23(2): 107-108,111.
30. Xu C, Pang Y, Li R, et al. Clinical outcome of multidrug-resistant tuberculosis patients receiving standardized second-line treatment regimen in China. J Infect, 2018, 76(4): 348-353.
31. Lv L, Li T, Xu K, et al. Sputum bacteriology conversion and treatment outcome of patients with multidrug-resistant tuberculosis. Infect Drug Resist, 2018, 11: 147-154.
32. Zhang L, Meng Q, Chen S, et al. Treatment outcomes of multidrug-resistant tuberculosis patients in Zhejiang, China, 2009-2013. Clin Microbiol Infect, 2018, 24(4): 381-388.
33. Fan YM, Ding SP, Bao ZJ, et al. Prognostic factors for treatment success in patients with multidrug-resistant tuberculosis in China. Int J Tuberc Lung Dis, 2018, 22(3): 300-305.
34. 包昌琳, 易恒仲, 唐益, 等. 耐多藥肺結核患者化學治療療效及其影響因素分析. 中國防癆雜志, 2018, 40(5): 525-530.
35. 陳壯濠, 林健雄, 李鴻檳, 等. 汕頭市耐多藥結核病患者治療情況分析. 臨床肺科雜志, 2018, 23(10): 1850-1853.
36. Chen Y, Yuan Z, Shen X, et al. Time to multidrug-resistant tuberculosis treatment initiation in association with treatment outcomes in Shanghai, China. Antimicrob Agents Chemother, 2018, 62(4): e02259-17.
37. Li Q, Shi CX, Lu M, et al. Treatment outcomes of multidrug-resistant tuberculosis in Hangzhou, China, 2011 to 2015. Medicine (Baltimore), 2020, 99(30): e21296.
38. Zheng XB, Diwan VK, Zhao Q, et al. Treatment quality and outcome for multidrug-resistant tuberculosis patients in four regions of China: a cohort study. Infect Dis Poverty, 2020, 9(1): 97.
39. 蔡春葵, 楊連軍, 王申蓮, 等. 316例耐多藥肺結核患者的治療結果分析. 中國醫藥指南, 2020, 18(22): 41-42.
40. 簡麗萍, 郭子玉, 鄧笑媚, 等. 耐多藥肺結核療效影響因素的研究. 中國醫藥科學, 2020, 10(13): 191-194.
41. Liu Q, Yang D, Qiu B, et al. Drug resistance gene mutations and treatment outcomes in MDR-TB: a prospective study in Eastern China. PLoS Negl Trop Dis, 2021, 15(1): e0009068.
42. Zhang MW, Zhou L, Zhang Y, et al. Treatment outcomes of patients with multidrug and extensively drug-resistant tuberculosis in Zhejiang, China. Eur J Med Res, 2021, 26(1): 31.
43. 張夢嫻, 楊成鳳, 葉建君, 等. 1447例耐多藥肺結核患者治療轉歸隊列分析. 公共衛生與預防醫學, 2020, 31(3): 68-72.
44. Arnold A, Cooke GS, Kon OM, et al. Drug resistant TB: UK multicentre study (DRUMS): treatment, management and outcomes in London and West Midlands 2008-2014. J Infect, 2017, 74(3): 260-271.
45. Riccardi N, Saderi L, Borroni E, et al. Therapeutic strategies and outcomes of MDR and pre-XDR-TB in Italy: a nationwide study. Int J Tuberc Lung Dis, 2021, 25(5): 395-399.
46. Henry B, Revest M, Dournon N, et al. Preliminary favorable outcome for medically and surgically managed extensively drug-resistant tuberculosis, France, 2009-2014. Emerg Infect Dis, 2016, 22(3): 518-521.
47. Eshetie S, Alebel A, Wagnew F, et al. Current treatment of multidrug resistant tuberculosis in Ethiopia: an aggregated and individual patients' data analysis for outcome and effectiveness of the current regimens. BMC Infect Dis, 2018, 18(1): 486.
48. Alemu A, Bitew ZW, Worku T. Poor treatment outcome and its predictors among drug-resistant tuberculosis patients in Ethiopia: a systematic review and meta-analysis. Int J Infect Dis, 2020, 98: 420-439.
49. Alene KA, Viney K, McBryde ES, et al. Treatment outcomes in patients with multidrug-resistant tuberculosis in north-west Ethiopia. Trop Med Int Health, 2017, 22(3): 351-362.
50. Ahmed A, Mekonnen D, Shiferaw AM, et al. Incidence and determinants of tuberculosis infection among adult patients with HIV attending HIV care in north-east Ethiopia: a retrospective cohort study. BMJ Open, 2018, 8(2): e016961.
51. 中華人民共和國國務院辦公廳. 全國結核病防治規劃(2011-2015). Available at: http://www.gov.cn/zwgk/2011-12/06/content_2012869.htm.
52. 中華人民共和國國務院辦公廳. 《“十三五”全國結核病防治規劃》. Available at: http://www.gov.cn/xinwen/2017-02/16/content_5168549.htm.
53. 鄺浩斌, 謝育紅, 馮治宇, 等. 2014-2019年廣州市耐多藥肺結核管理策略實施效果分析. 中國防癆雜志, 2021, 43(2): 113-118.
54. 趙秀娟, 劉琳, 吳興勇, 等. 海南省369例耐多藥肺結核患者流行病學特征分析. 海南醫學院學報, 2021. DOI: 10.13210/j.cnki.jhmu.20210413.002.
55. 王云霞, 鄭娟娟, 張娟娟, 等. 2011-2018年寶安區肺結核患者耐多藥的影響因素分析. 預防醫學, 2021, 33(7): 701-703.
56. 全國第五次結核病流行病學抽樣調查技術指導組, 全國第五次結核病流行病學抽樣調查辦公室. 2010年全國第五次結核病流行病學抽樣調查報告. 中國防癆雜志, 2012, 34(8): 485-508.
57. 陜俊玲, 薛王謙, 韓亞男. 涂陽肺結核139例患者分枝桿菌培養及藥敏分析. 中國藥物與臨床, 2013, 13(z1): 10-11.
58. 李秀杰. 172例耐多藥結核病患者特征及治療轉歸的影響因素分析. 中國現代醫生, 2019, 57(7): 30-32.
59. 李雪, 李楠楠, 任斐, 等. 耐多藥肺結核合并糖尿病的臨床特點及治療結局. 中國熱帶醫學, 2021.
60. 周銀發, 張山鷹, 柳珍妮, 等. 242例耐多藥結核病患者特征及治療轉歸的影響因素分析. 中國防癆雜志, 2017, 39(11): 1218-1222.

Previous Article
Pay-for-performance for primary care physicians: a systematic review
Next Article
Clinical practice guidelines of bronchoalveolar lavage: a methodological quality study

Chinese Journal of Evidence-Based Medicine

Treatment outcomes of multidrug-resistant tuberculosis patients in China: a meta-analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content